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Abstract Increased flux through the hexosamine biosynthetic
pathway with glutamine:fructose-6-phosphate-amidotransferase
(GFAT) as rate-limiting enzyme has been linked to the enhanced
bioactivity of the prosclerotic cytokine transforming growth
factor L1 (TGF-L1) in fibrotic complications, particularly in
diabetic kidney disease. Here, we investigate in a stable
transfection system the effect of overexpression of GFAT on
TGF-L1 synthesis in NIH-3T3 fibroblasts. We demonstrate a
1.8-fold stimulation of TGF-L1 mRNA and a 1.9-fold increased
protein expression, whereas TGF-L2 production was not
upregulated. The 1.5-fold enhanced TGF-L1 promoter activity
suggests a transcriptional regulation. The elevated TGF-L1
protein is biologically active since GFAT-overexpressing cells
exhibit a 2-fold fibronectin production. The results indicate a
GFAT-dependent induction of TGF-L1 synthesis. ß 2001 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Glutamine:fructose-6-phosphate-amidotransferase (GFAT)
is the rate-limiting enzyme of the hexosamine biosynthetic
pathway, catalyzing the conversion of fructose-6-phosphate
to glucosamine-6-phosphate (GlcN-6-P) with glutamine as
amino donor [1^3]. The product GlcN-6-P is very rapidly
further converted and activated to uridine-5-diphosphate-N-
acetylglucosamine (UDP-GlcNAc), a precursor for the bio-
synthesis of the carbohydrate moiety of glycoproteins, glyco-
lipids and proteoglycans. GFAT controls the £ux of glucose
into the hexosamine pathway [4], and thus the availability of
precursors for N- and O-linked glycosylation of proteins. Ac-
cordingly, GFAT expression is highly regulated, e.g. in yeast
[5] and in human tissues [6]. Recent studies indicate that
GFAT, besides its key role in the synthesis of amino sugar
precursors, may have regulatory functions. These include the
¢ndings that the hexosamine pathway may serve as a nutrient-
sensing pathway [7] and that it may mediate glucose-induced
insulin-resistance [2,4,8,9]. Furthermore, this pathway has
been linked to the development of diabetes-associated macro-
vascular complications [10^12] and glomerulosclerosis [13,14].
The hyperglycemia-induced overexpression of the prosclerotic
cytokine transforming growth factor L1 (TGF-L1) has been
shown to be involved in the pathogenesis of diabetic renal
¢brosis [15^17]. TGF-L1 acts as a key mediator with its ¢bro-
genic potential to stimulate matrix synthesis and to inhibit
matrix degradation [18^22] and by interaction with the re-
nin^angiotensin system [23]. It was reported previously that
the high-glucose-induced overexpression of TGF-L1 in renal
mesangial cells is mediated by the hexosamine pathway, since
increased £ux through this pathway induced by ambient high
glucose or glucosamine causes enhanced TGF-L1 production
[13]. Furthermore, inhibition of GFAT expression by anti-
sense oligonucleotides or application of the GFAT inhibitor
azaserine prevented the expression of biologically active TGF-
L1 [13]. These results suggest a role of the hexosamine path-
way in the regulation of TGF-L1 expression.
To assess the role of increased GFAT expression in TGF-
L1-mediated tissue ¢brosis we investigated in a stable trans-
fection system the e¡ect of overexpression of GFAT on TGF-
L1 expression in NIH-3T3 ¢broblasts. We demonstrate that
increase of GFAT protein enhances TGF-L1 mRNA and
TGF-L1 protein production and that the stimulatory e¡ect
may be mediated by activation of TGF-L1 promoter activity.
2. Materials and methods
2.1. Preparation of GFAT expression vector
A full-length GFAT cDNA was generated by reverse transcriptase-
polymerase chain reaction using RNA of human B-lymphocytes
as template with the primer 5P-CGGATCCCGCATCATGTGTGG-
TATATTT-3P and 5P-GGAATTCCGTATAGATTCCTCACTCT-3P
which contain BamHI or EcoRI linker. The PCR-product was cloned
into the expression vector pJ66 (American Type Culture Collection,
Rockville, USA) and veri¢ed by sequencing. The GFAT cDNA was
identical to human GFAT (GenBank accession number M90516).
2.2. Culture and transfection of NIH-3T3 ¢broblasts
Fibroblasts were cultured with DMEM medium containing 25 mM
glucose, 10% fetal calf serum, 1 mM sodium pyruvate, 4 mM gluta-
mine, non-essential amino acids, 100 U/ml penicillin and 100 Wg/ml
streptomycin (Gibco, Eggenstein, Germany). For experiments
DMEM medium contains 5.5 mM glucose and fetal calf serum was
substituted with 2% Ultroser (Gibco, Eggenstein, Germany). For de-
termination of TGF-L1 protein in the cell culture supernatant, serum-
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free medium was used. Fibroblasts were transfected with Superfect
(Qiagen, Hilden, Germany) according to the instructions of the sup-
plier. 1U105 cells in a 6-cm dish received 4.5 Wg pJ66GFAT or pJ66
as control and 0.5 Wg pSVneo encoding neomycin resistance. Trans-
fected cells were selected for their resistance to the antibiotic G418
(0.5 Wg/ml). G418-resistant clones were screened for expression of
GFAT by Western blotting. For determination of TGF-L1 promoter
activity 1.5U105 GFAT transfectants or controls were seeded in 6-
well plates and transfected with 1.75 Wg pGL3TGF-L1 containing the
human TGF-L1 promoter region 3453/+11 [24] fused to the ¢re£y
(Photinus pyralis) luciferase gene (provided from A. Pfei¡er, Bochum,
Germany) and 0.25 Wg pRL-CMV (Promega, Madison, WI, USA) for
standardization of transfection e⁄ciencies. Transfection was per-
formed with Superfect. Transfected cells were harvested after 24 h
and reporter gene activities were measured.
2.3. Western blot
Cellular extracts of GFAT transfectants or controls were applied to
sodium dodecyl sulfate (SDS) gel electrophoresis and Western blotting
was performed as recently described [13].
2.4. Determination of UDP-GlcNAc
Cell extracts were prepared and UDP-GlcNAc was determined by
capillary electrophoresis as described previously [25].
2.5. Determination of glucose, lactate and DNA concentrations
In supernatants glucose and lactate were measured with Ektachem
Vitros systems (Ortho-clinical-diagnostics, Neckargmu«nd, Germany).
DNA in total cell extracts was measured by £uorometry with bis-
benzimidazole [18].
2.6. Northern blotting
RNA was prepared from cultured GFAT transfectants and controls
with the RNeasy kit (Qiagen, Hilden, Germany). Total RNA (25 Wg)
was separated on a formaldehyde-containing agarose gel and trans-
ferred to a Nylon membrane. RNA probes for TGF-L1 and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) are described previ-
ously [13] and digoxigenin-labelled by in vitro transcription.
Hybridization was performed overnight in 5Usodium chloride sodium
citrate (SSC), 50% formamide, 0.1% N-lauroylsarcosine, 0.02% SDS,
2% blocking reagent (Roche, Mannheim, Germany) at 68‡C, and the
¢lters were then washed with 2USSC, 0.1% at room temperature and
0.5USSC, 0.1% SDS at 68‡C. For detection the DIG Luminescent
Detection kit (Roche, Mannheim, Germany) was used.
2.7. ELISA for TGF-L1, TGF-L2 and ¢bronectin
For quanti¢cation of the proteins cell culture supernatants were
collected and stored at 380‡C. Determinations of total TGF-L1 and
-L2 protein were performed with the Quantikine Immunoassays (RpD
Systems, Minneapolis, MN, USA). Fibronectin was measured by the
Quantimatrix1 human ¢bronectin ELISA kit from Chemicon Inter-
national (Temecula, CA, USA).
2.8. Reporter gene assays
Transfected cells were washed once with phosphate-bu¡ered saline,
incubated with 150 Wl lysis bu¡er from the L-galactosidase assay
chemiluminescent (Roche, Mannheim, Germany) for 30 min and har-
vested. Cotransfected ¢re£y and seapansy luciferase activities were
assayed with the dual-luciferase reporter assay system (Promega,
Madison, WI, USA). Chemiluminescence was determined with a Mag-
ic Lite Analyzer (Ciba Corning, Fernwald, Germany). All transfection
experiments were repeated at least three times.
2.9. Statistical analysis
Results presented are derived from at least three independent ex-
periments. Means þ S.E.M. were calculated and groups of data were
compared using Student’s t-test. Statistical signi¢cance was set at
P6 0.05.
3. Results
A stable transfection system was used to evaluate the role
of the hexosamine biosynthetic pathway in regulating expres-
sion of the TGF-L1. The full-length cDNA of the rate-limiting
enzyme of this pathway, GFAT, was inserted into the expres-
Fig. 1. Overexpression of GFAT in NIH-3T3 ¢broblasts. A: GFAT
transfectants and controls were generated as described in Section 2
and GFAT expression was determined by Western blotting. Three
control and GFAT clones were tested. The band of the 80-kDa pro-
tein of GFAT is marked by an arrow. B: In cell extracts of controls
and GFAT transfectants the concentration of UDP-GlcNAc after
24 and 48 h cell culture was measured by capillary electrophoresis.
Bar graphs show nmol UDP-GlcNAc normalized to DNA concen-
tration of the cells. The error bars mark þ S.E.M. *P6 0.05 vs.
control (24 h).
Fig. 2. Lactate production, glucose uptake, and cell proliferation of
controls and GFAT transfectants during 48 h cell culture. Superna-
tants of controls and GFAT transfectants were collected after 12,
24 and 48 h of cell growth and lactate (A) and glucose (B) were
measured as described in Section 2. Total cell extracts were pre-
pared after 12, 24 and 48 h of growing, and DNA was determined
(C).
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sion vector pJ66 downstream of the rat L-actin promoter.
The GFAT gene construct was introduced into NIH-3T3 ¢-
broblasts by Superfect and G418-resistant clones were eval-
uated for GFAT protein expression by Western blotting and
activity of the hexosamine pathway by determination of intra-
cellular UDP-GlcNAc. The expression of GFAT protein in
stable transfectants was increased 2.6-fold in three di¡erent
clones compared to three di¡erent controls (Fig. 1A). The
concentration of the end-product of the hexosamine biosyn-
thetic pathway, UDP-GlcNAc, was 6.02 þ 0.5 nmol/Wg DNA
in the GFAT-overexpressing ¢broblasts after 24 h culture,
while in controls only 2.97 þ 0.41 nmol/Wg DNA were found
(Fig. 1B). After 48 h control cells contained 6.73 þ 1.2 nmol
UDP-GlcNAc/Wg DNA and GFAT transfectants 8.04 þ 0.5
nmol UDP-GlcNAc/Wg DNA (Fig. 1B). Since glucose uptake
and lactate production and thus £ux through glycolysis were
unchanged in the GFAT-overexpressing ¢broblasts (Fig.
2A,B), the enhanced £ux through the hexosamine biosynthetic
pathway indicates an increase in enzymatically active GFAT
protein. GFAT overexpression had only marginal e¡ects on
cell proliferation (Fig. 2C).
We studied then whether the expression of the TGF-L1
mRNA and protein was altered by overexpression of
GFAT. After 24 h cell culture TGF-L1 mRNA was increased
in GFAT clones, while in control cells only marginal amounts
of TGF-L1 mRNA were detected (Fig. 3A). Evaluation of
three independent experiments showed a 1.8-fold increase of
TGF-L1 mRNA in GFAT transfectants compared to controls
(Fig. 3B). In accordance with the elevated TGF-L1 mRNA-
levels after 24 h an increase of secreted TGF-L1 protein was
observed after 24 h, which was enhanced 1.9-fold after 48 h in
GFAT-overexpressing ¢broblasts (Fig. 4A). To con¢rm the
speci¢city of GFAT-dependent upregulation of TGF-L1 ex-
pression, the concentration of secreted TGF-L2 protein was
measured. The time course of TGF-L2 production reached the
maximum after 24 h, after 48 h no further elevation of TGF-
L2 was found (data not shown). No signi¢cant increase in
TGF-L2 protein concentration was observed in GFAT-trans-
fected cells after 12 and 24 h compared to controls (Fig. 4B).
Fig. 3. E¡ect of GFAT overexpression on TGF-L1 mRNA expres-
sion. Controls and GFAT transfectants were cultured for 24 h (A,
B). Total RNA (25 Wg) was separated on agarose^formaldehyde gels
and transferred onto nylon membranes for hybridization with digox-
igenin-labelled TGF-L1 or GAPDH probes. A: Representative
Northern blot with two di¡erent clones of controls and GFAT
transfectants harvested after 24 h cell culture. B: Densities of TGF-
L1 mRNA signals were normalized relative to those of GAPDH
mRNA signals. Ratio of control cells was set as 1. Results are ex-
pressed as mean þ S.E.M. of three separate experiments. *P6 0.05
vs. control.
Fig. 4. E¡ect of GFAT overexpression on TGF-L1 and -L2 protein
production. Supernatants of control and GFAT transfectants are
collected after the indicated time of cell culture and total TGF-L1
and -L2 protein was measured by ELISA. A: Concentration of
TGF-L1 after 24 and 48 h. Bar graphs show pg TGF-L1 protein
normalized to DNA content of the cells. The error bars mark
þ S.E.M. *P6 0.05 vs. control. B: Concentration of TGF-L2 after
12 and 24 h. The earlier points of time were shown since after 48 h
no further production of TGF-L2 was found. Bar graphs show pg
TGF-L2 protein normalized to the DNA content of the cells.
Fig. 5. E¡ect of GFAT overexpression on TGF-L1 promoter activ-
ity. Transfection of controls and GFAT transfectants with
pGL3TGF-L1, containing the TGF-L1 promoter region 3453 to
+11, and reporter gene assays were performed as described in Sec-
tion 2. Bar graphs show relative luciferase activities normalized to
cotransfected control vector pRL-CMV. Promoter activity of con-
trol cells was set as 100%. The error bar marks þ S.E.M. *P6 0.05
vs. control.
FEBS 24485 9-1-01
C. Weigert et al./FEBS Letters 488 (2001) 95^99 97
In addition, the activity of the TGF-L1 promoter region 3453
to +11 containing the regulatory elements for basal promoter
function [24], phorbol-ester-responsiveness [26], autoinduction
[27], and high-glucose-responsiveness [28] was investigated in
GFAT transfectants. In ¢broblasts overexpressing GFAT, the
activity of the cotransfected TGF-L1 promoter construct was
146% compared to control cells (Fig. 5). These results suggest
that the GFAT-induced increase in TGF-L1 mRNA and pro-
tein levels is regulated by transcriptional activation of the
TGF-L1 gene. To evaluate if the increased TGF-L1 expression
is biologically active the production of the TGF-L1-responsive
gene ¢bronectin was studied. We found a 2-fold increased
production of ¢bronectin after 72 h but not after 48 h (Fig.
6) indicating (i) that enhanced TGF-L1 expression precedes
¢bronectin production and (ii) that the GFAT-induced
TGF-L1 protein is biologically active.
4. Discussion
In a previous report it was demonstrated that increased £ux
through the hexosamine biosynthetic pathway by high glucose
or glucosamine led to increased concentrations of the pro-
sclerotic TGF-L1 [13], a cytokine which has been implicated
in the development of diabetic late complications, e.g. diabetic
nephropathy and vasculopathies [15^23]. In the present study
we established a stable transfection system in NIH-3T3 ¢bro-
blasts to clarify whether overexpression of the rate-limiting
enzyme of the hexosamine biosynthetic pathway, GFAT, in-
dependent of the presence of high glucose concentrations, in-
duces the synthesis of TGF-L1. The 2.6-fold overexpression of
GFAT led to an elevated concentration of UDP-GlcNAc, the
end-product of the hexosamine biosynthetic pathway, after
24 h. The lower increase after 48 h may be explained by the
negative feedback inhibition of GFAT enzyme activity by
UDP-GlcNAc [1,3]. In this stable transfection system we ob-
tained clear evidence for an involvement of the hexosamine
biosynthetic pathway in the up-regulation of TGF-L1 synthe-
sis. We demonstrated an increase of TGF-L1 mRNA and
protein levels as well as a stimulated TGF-L1 promoter activ-
ity in ¢broblasts overexpressing GFAT. This induction
appeared to be speci¢c since TGF-L2 production was not
a¡ected. Furthermore we found an enhanced TGF-L1 bio-
activity since the expression of the TGF-L1 responsive gene
¢bronectin was elevated in the GFAT-transfected cells. These
results indicate that an increased £ux through the hexosamine
biosynthetic pathway induced by high glucose or by an in-
crease of GFAT protein in normal glucose concentrations
stimulate TGF-L1 synthesis and action. The latter observation
may be important since an increased amount of GFAT pro-
tein was detected in renal sections of diabetic patients [6] and
in skeletal muscle and in cultured skeletal muscle cells ob-
tained from diabetic patients increased enzyme activity was
measured [29,30]. The activation of the TGF-L1 promoter
activity gives rise to a transcriptional regulation of the en-
hanced TGF-L1 synthesis by the hexosamine biosynthetic
pathway, comparable with the hexosamine pathway-depen-
dent enhanced gene expression of the epithelial growth fac-
tor-like transforming growth factor K in smooth muscle cells
[10^12]. Since the UDP-sugars generated by this pathway are
precursors for glycosylated proteins, the regulation of tran-
scription factors by altered glycosylation must be considered
[31]. Suggested mechanisms include altered proteolytic degra-
dation [32] or changes in the trans-acting activity of transcrip-
tion factors [31], e.g. by alternative phosphorylation or glyco-
sylation of the same residues [33]. Since the activity of the
ubiquitous transcription factor stimulatory protein 1 (Sp1),
which is involved in the TGF-L1 promoter activation [24], is
regulated by O-glycosylation [32,34], the increased TGF-L1
gene expression in GFAT-overexpressing NIH-3T3 cells may
be mediated by altered glycosylation of Sp1.
In conclusion, the results of the present study demonstrate
the importance of the hexosamine biosynthetic pathway in the
speci¢c upregulation of the prosclerotic cytokine TGF-L1
thereby suggesting that an increase in the rate-limiting enzyme
GFAT is involved in the development of tissue ¢brosis, e.g. in
the pathogenesis of vascular complications in diabetes.
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